Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 886 to 900 of 1339 results for 0

  1. d-Nav insulin management app for type 2 diabetes (MIB285)

    NICE has developed a medtech innovation briefing (MIB) on d-Nav insulin management app for type 2 diabetes .

  2. Cancer: breast screening (53 to 70 years) (IND65)

    This indicator covers the proportion of women aged 53 to 70 years whose record shows a breast screening test has been performed within the last 3 years. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG84

  3. CORTRAK 2 Enteral Access System for placing nasoenteral feeding tubes (MIB48)

    NICE has developed a medtech innovation briefing (MIB) on the CORTRAK 2 Enteral Access System for placing nasoenteral feeding tubes .

  4. Off-pump coronary artery bypass grafting (IPG377)

    Evidence-based recommendations on off-pump coronary artery bypass grafting. This involves attaching a healthy blood vessel to the heart muscle so that blood can get round (‘bypass’) the affected part of the coronary artery.

  5. Faecal microbiota transplant for recurrent Clostridioides difficile infection (MTG71)

    Evidence-based recommendations on faecal microbiota transplant for recurrent Clostridioides difficile infection.

  6. Artificial intelligence in mammography (MIB242)

    NICE has developed a medtech innovation briefing (MIB) on artificial intelligence in mammography .

  7. Therapeutic amnioinfusion for oligohydramnios during pregnancy (excluding labour) (IPG192)

    Evidence-based recommendations on therapeutic amnioinfusion for treating oligohydramnios during pregnancy (excluding labour). This involves injecting a substance similar to amniotic fluid into the space around the baby.

  8. Entrectinib for treating NTRK fusion-positive solid tumours (TA644)

    Evidence-based recommendations on entrectinib (Rozlytrek) for treating neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours in adults and children over 12 years.

  9. Stent-graft placement in abdominal aortic aneurysm (IPG163)

    Evidence-based recommendations on stent-graft placement in abdominal aortic aneurysm. This involves patching the weakened section of the aorta with a graft mounted on a stent.

  10. Soft-palate implants for obstructive sleep apnoea (IPG241)

    Evidence-based recommendations on soft-palate implants for obstructive sleep apnoea. This involves inserting implants into the soft palate of the mouth to stiffen it over subsequent weeks and make it less likely to vibrate.

  11. Implantation of multifocal (non-accommodative) intraocular lenses during cataract surgery (IPG264)

    Evidence-based recommendations on the implantation of multifocal (non-accommodative) intraocular lenses during cataract surgery. This involves replacing the clouded lens with an artificial one with areas of different focusing power to allow near and distant objects to be seen.

  12. Functional electrical stimulation for drop foot of central neurological origin (IPG278)

    Evidence-based recommendations on functional electrical stimulation for drop foot of central neurological origin. This involves stimulating the peripheral nerves that supply the paralysed muscle using electrodes to restore muscular function.

  13. Angioplasty and stenting to treat peripheral arterial disease causing refractory erectile dysfunction (IPG546)

    Evidence-based recommendations on angioplasty and stenting to treat peripheral arterial disease causing refractory erectile dysfunction in adults. This involves using a device to improve blood flow to the penis.

  14. Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (HST12)

    Evidence-based recommendations on cerliponase alfa (Brineura) for treating neuronal ceroid lipofuscinosis type 2 in children.

  15. Strimvelis for treating adenosine deaminase deficiency–severe combined immunodeficiency (HST7)

    Evidence-based recommendation on Strimvelis for adenosine deaminase deficiency–severe combined immunodeficiency.